M edical device company Globus Medical (NYSE:GMED) in Q1 CY2025, with sales falling 1.4% year on year to $598.1 million. On the other hand, the company’s full-year revenue guidance of $2.85 ...

This article was originally published on Quiver News, read the full story. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of ...

Globus Medical GMED continues to gain from surging demand for its Musculoskeletal Solutions products. Meanwhile, the company’s series of product launches aid growth. The stock sports a Zacks ...

AUDUBON, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth ...

Globus Medical reports quarterly earnings of 72 cents per share which beat the analyst consensus estimate of 57 cents by 26.32%. Quarterly sales come in at $606.67 million which beat the analyst ...

Globus Medical announced the unexpected resignation of CEO Dave Demski. The company also provided preliminary Q1 sales that were lower than expected. Dave Demski had been with Globus for 20 years ...

Although the company reported solid sales for 3Q23 ... seems to have led Lichtman to retain a Hold rating for Globus Medical. According to TipRanks, Lichtman is a 5-star analyst with an average ...